Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: VLV011
MIFTS: 51

Vulvovaginal Candidiasis

Categories: Infectious diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Vulvovaginal Candidiasis

About this section

MalaCards integrated aliases for Vulvovaginal Candidiasis:

Name: Vulvovaginal Candidiasis 12 3 15
Candidiasis, Vulvovaginal 44 73
Candidiasis of Vulva and Vagina 12
Candidiasis Vulvovaginal 55
Candidal Vulvovaginitis 12
Monilial Vulvovaginitis 12

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:2272
ICD10 33 B37.3
ICD9CM 35 112.1
MeSH 44 D002181
NCIt 50 C2914
SNOMED-CT 68 72605008
UMLS 73 C0700345
Sources

Summaries for Vulvovaginal Candidiasis

About this section
CDC : 3 Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems. Sometimes Candida can multiply and cause an infection if the environment inside the vagina changes in a way that encourages its growth. Candidiasis in the vagina is commonly called a “vaginal yeast infection.” Other names for this infection are “vaginal candidiasis,” “vulvovaginal candidiasis,” or “candidal vaginitis.”

MalaCards based summary : Vulvovaginal Candidiasis, also known as candidiasis, vulvovaginal, is related to candidiasis and bacterial vaginosis. An important gene associated with Vulvovaginal Candidiasis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Clindamycin and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and colon, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A candidiasis that involves fungal infection of the vaginal mucous membranes in women caused by Candida albicans. The symptoms include intense vulval pruritus, burning, erythema and dyspareunia associated with a creamy white, curd-like discharge.

Wikipedia : 76 Vaginal yeast infection, also known as candidal vulvovaginitis and vaginal thrush, is excessive growth... more...

Sources

Related Diseases for Vulvovaginal Candidiasis

About this section

Diseases related to Vulvovaginal Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Related Disease Score Top Affiliating Genes
1 candidiasis 32.2 CLEC7A DEFB4A MBL2
2 bacterial vaginosis 30.9 DEFB4A MBL2 TLR2
3 vulvar vestibulitis syndrome 30.3 MBL2 NLRP3
4 oral candidiasis 30.2 DEFB1 DEFB4A
5 candida glabrata 10.4
6 trichomoniasis 10.3
7 diabetes mellitus 10.2
8 vulvovaginitis 10.2
9 coccidioidomycosis 10.2 CLEC7A MBL2
10 immunoglobulin g deficiency 10.2 CD79A MBL2
11 immunoglobulin alpha deficiency 10.2 CD79A MBL2
12 corneal abscess 10.2 DEFB1 DEFB4A
13 prosthetic joint infection 10.2 MBL2 TLR2
14 osteonecrosis of the jaw 10.2 DEFB1 DEFB4A
15 tularemia 10.1 MBL2 TLR2
16 fungal keratitis 10.1 CLEC7A TLR2
17 neisseria meningitidis infection 10.1 MBL2 TLR2
18 haemophilus influenzae 10.1 CLEC7A TLR2
19 localized scleroderma 10.1 DEFB1 DEFB4A
20 clonorchiasis 10.1 CD79A IL2
21 septic arthritis 10.1 DEFB4A TLR2
22 microscopic colitis 10.1 CD79A IL2
23 mycobacterium kansasii 10.1 NLRP3 TLR2
24 extrapulmonary tuberculosis 10.1 MBL2 TLR2
25 cervicitis 10.1 DEFB4A IL2
26 hematopoietic stem cell transplantation 10.1 CLEC7A IL2
27 invasive aspergillosis 10.0 CLEC7A MBL2 TLR2
28 congenital hypogammaglobulinemia 10.0 CD79A IL4
29 sebaceous gland disease 10.0 CD79A DEFB4A TLR2
30 immunodeficiency with hyper-igm, type 1 10.0 CD79A IL4
31 chromoblastomycosis 10.0 CLEC7A IL4
32 orofacial granulomatosis 10.0 CD79A IL4
33 rheumatic fever 10.0 IL2 MBL2
34 wells syndrome 10.0 IL2 NLRP3
35 allergic bronchopulmonary aspergillosis 10.0 IL4 MBL2
36 diabetes mellitus, noninsulin-dependent 10.0
37 multiple sclerosis 10.0
38 cystic fibrosis 10.0
39 human immunodeficiency virus type 1 10.0
40 deficiency anemia 10.0
41 iron deficiency anemia 10.0
42 iron metabolism disease 10.0
43 human immunodeficiency virus infectious disease 10.0
44 lichen sclerosus 10.0
45 cryptococcosis 10.0 IL4 MBL2
46 folliculitis 10.0 DEFB4A IL4
47 milk allergy 10.0 CD79A IL4
48 neurofibromatosis, type ii 10.0 DEFB1 DEFB4A TLR2
49 meningitis 10.0 MBL2 NLRP3 TLR2
50 mycobacterium abscessus 10.0 CLEC7A NLRP3 TLR2

Comorbidity relations with Vulvovaginal Candidiasis via Phenotypic Disease Network (PDN): (show all 12)


Acute Cystitis Anxiety
Bronchitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Heart Disease Hypertension, Essential
Hypothyroidism Oral Candidiasis
Osteoporosis Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Vulvovaginal Candidiasis:



Diseases related to Vulvovaginal Candidiasis
Sources

Symptoms & Phenotypes for Vulvovaginal Candidiasis

About this section

MGI Mouse Phenotypes related to Vulvovaginal Candidiasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.86 CD101 CD79A CLEC7A IL2 IL4 MBL2
2 immune system MP:0005387 9.76 CD101 CD79A CLEC7A IL2 IL4 MBL2
3 digestive/alimentary MP:0005381 9.72 CLEC7A IL2 IL4 NLRP3 TLR2
4 liver/biliary system MP:0005370 9.35 CD79A IL2 IL4 NLRP3 TLR2
5 renal/urinary system MP:0005367 9.02 CD79A IL4 MBL2 NLRP3 TLR2
Sources

Drugs & Therapeutics for Vulvovaginal Candidiasis

About this section

Drugs for Vulvovaginal Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1,Not Applicable 18323-44-9 29029
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
3
Clotrimazole Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 23593-75-1 2812
4
Fluconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 86386-73-4 3365
5
Dequalinium Approved, Investigational Phase 4 6707-58-0
6
Terconazole Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 67915-31-5 441383
7
Metronidazole Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 443-48-1 4173
8 Antibiotics, Antitubercular Phase 4,Phase 3,Not Applicable
9 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Clindamycin palmitate Phase 4,Phase 3,Early Phase 1,Not Applicable
13 Antitubercular Agents Phase 4,Phase 3
14 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Clindamycin phosphate Phase 4,Phase 3,Early Phase 1,Not Applicable
19 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
20 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Anti-Infective Agents, Local Phase 4,Phase 3
24 Immune Sera Phase 4
25 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2
26
Amphotericin B Approved, Investigational Phase 3,Phase 2 1397-89-3 5280965 14956
27
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
28
Ketoconazole Approved, Investigational Phase 3 65277-42-1 3823 47576
29
Rifabutin Approved, Investigational Phase 3 72559-06-9 6323490
30
Azithromycin Approved Phase 3 83905-01-5 55185 447043
31
Tinidazole Approved, Investigational Phase 3 19387-91-8 5479
32
leucovorin Approved Phase 3 58-05-9 6006 143
33
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
34
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
35 Antiparasitic Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
36 Liposomal amphotericin B Phase 3,Phase 2
37 Antiprotozoal Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
38 Alkylating Agents Phase 3
39 Antirheumatic Agents Phase 3
40 Folic Acid Antagonists Phase 3
41 Immunosuppressive Agents Phase 3
42 Vitamin B9 Phase 3
43 Vitamin B Complex Phase 3
44 Dermatologic Agents Phase 3
45 Antimetabolites, Antineoplastic Phase 3
46 Folate Phase 3
47 Antimetabolites Phase 3
48 Nucleic Acid Synthesis Inhibitors Phase 3
49
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
50
Titanium dioxide Approved Phase 2 13463-67-7

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Unknown status NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
2 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
3 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
4 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
5 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
6 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4 Miconazole nitrate
7 Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
8 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3 Fluconazole
9 Diabetes Mellitus and Vulvovaginal Candidiasis Completed NCT00353561 Phase 3 Boric;Fluconazole
10 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
11 A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
12 Comparative Efficacy of Ovule vs Tablet Completed NCT00755053 Phase 3 Clotrimazole, vaginal ovule;Clotrimazole, vaginal tablet
13 A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients Completed NCT00002122 Phase 3 Azithromycin;Rifabutin;Fluconazole
14 Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
15 A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants Completed NCT01941940 Phase 3 Tocilizumab;DMARDs
16 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Recruiting NCT03562156 Phase 3 VT-1161;Placebo
17 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Recruiting NCT03561701 Phase 3 VT-1161;Placebo
18 Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis Recruiting NCT03734991 Phase 3 Ibrexafungerp;Placebo
19 ProF-001_Phase IIa Recruiting NCT03115073 Phase 2, Phase 3 Candiplus;Clotrimazole
20 Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream. Recruiting NCT03005353 Phase 2, Phase 3 Cumin seed extract;clotrimazole
21 Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis Not yet recruiting NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
22 Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis Not yet recruiting NCT03473418 Phase 3 Ketoconazole;Terconazole
23 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Completed NCT02267382 Phase 2 VT-1161;Placebo
24 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
25 MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2 MGCD290
26 Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2 SCY-078;Fluconazole
27 An Active-Controlled, Dose-Finding Study of SCY-078 vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03253094 Phase 2 Fluconazole;SCY-078
28 Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment Completed NCT01144286 Phase 2 arasertaconazole nitrate;placebo
29 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) Completed NCT01891331 Phase 2 VT-1161;Fluconazole
30 Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Completed NCT02971007 Phase 2 Oral Encochleated Amphotericin B (CAMB);Fluconazole
31 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women Completed NCT01230814 Phase 2 Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate);Placebo
32 RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections Completed NCT02733432 Phase 2 CD101 Vaginal Gel (3%);CD101 External gel (1%);CD101 Vaginal Ointment (6%);CD101 External ointment (1%);Fluconazole
33 TOL-463 Phase 2 Study for Vaginitis Completed NCT02866227 Phase 2 TOL-463;TOL-463
34 Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis Completed NCT00635622 Phase 2 LACTIN-V;Placebo control substance
35 Patients With Vulvovaginal Candidiasis Recruiting NCT03024502 Phase 1, Phase 2 EPP-AF Gel 1%;EPP-AF Gel 2%;Clotrimazole
36 Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Not yet recruiting NCT03167957 Phase 2 Oral Encochleated Amphotericin B (CAMB);Oral Encochleated Amphotericin B (CAMB)
37 Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status NCT00479947 Phase 1 Probiotics (Natural product);Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
38 Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection Completed NCT01067131 Phase 1
39 Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463 Completed NCT01812889 Phase 1 TOL-463 Vaginal ovule;TOL-463 Vaginal gel
40 Will Vaginal Colonization of Lactobacillus Increase Cure Rate After Treatment of Bacterial Vaginosis and Chronic Vulvovaginal Candida Unknown status NCT02295579
41 Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method Unknown status NCT02558179
42 Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis Completed NCT00803738 Not Applicable Terconazole Vaginal Suppository;Terazol Vaginal Suppository
43 Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) Completed NCT00895453 Not Applicable itraconazole;lactobacillus gasseri;classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)
44 A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations Completed NCT01039584 Not Applicable Butoconazole Nitrate Vaginal Cream;Placebo;Gynazole 1 vaginal cream
45 Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization Completed NCT02888197
46 Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis Completed NCT02203942
47 Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women Completed NCT02150655 Early Phase 1
48 Observational Program Neo-Penotran® Forte Completed NCT01335373 Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)
49 A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients Completed NCT00002438 Not Applicable Itraconazole
50 Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network Completed NCT00503542 Early Phase 1 Terazol or oral fluconazole for candidal vaginitis;Metronidazole or Clindamycin for Bacterial Vaginosis;Flagyl for definitively diagnosed vaginal trichomoniasis

Search NIH Clinical Center for Vulvovaginal Candidiasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: candidiasis, vulvovaginal

Sources

Genetic Tests for Vulvovaginal Candidiasis

About this section
Sources

Anatomical Context for Vulvovaginal Candidiasis

About this section

MalaCards organs/tissues related to Vulvovaginal Candidiasis:

41
Skin, Testes, Colon, Bone, Heart, Tonsil, Thyroid
Sources

Publications for Vulvovaginal Candidiasis

About this section

Articles related to Vulvovaginal Candidiasis:

(show top 50) (show all 452)
# Title Authors Year
1
Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. ( 29975334 )
2018
2
New evidence on oral L. plantarum P17630 product in women with history of recurrent vulvovaginal candidiasis (RVVC): a randomized double-blind placebo-controlled study. ( 29364495 )
2018
3
Risk Factors of Vulvovaginal Candidiasis among Women of Reproductive Age in Xi'an: A Cross-Sectional Study. ( 29977925 )
2018
4
Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study. ( 29790255 )
2018
5
A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate theA efficacy and safety of orally administeredA VT-1161 inA the treatment of recurrentA vulvovaginal candidiasis. ( 29534874 )
2018
6
Pulsatilla decoction inhibits Candida albicans proliferation and adhesion in a mouse model of vulvovaginal candidiasis via the Dectin-1 signaling pathway. ( 29775695 )
2018
7
Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis. ( 29963049 )
2018
8
Surface-modified mucoadhesive microgels as a controlled release system for miconazole nitrate to improve localized treatment of vulvovaginal candidiasis. ( 28986195 )
2018
9
Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: "Neutrophil Anergy". ( 29203543 )
2018
10
Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. isolated from vulvovaginal candidiasis. ( 29846682 )
2018
11
The effect of a vaginal suppository formulation of dill (Anethum graveolens) in comparison to clotrimazole vaginal tablet on the treatment of vulvovaginal candidiasis. ( 29553834 )
2018
12
Nanolipid Gel of an Antimycotic Drug for Treating Vulvovaginal Candidiasis-Development and Evaluation. ( 29340981 )
2018
13
Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. ( 29902998 )
2018
14
Thymol, eugenol and lactobacilli in a medical device for the treatment of bacterial vaginosis and vulvovaginal candidiasis. ( 29874389 )
2018
15
Amphotericin B-Loaded Plga Nanofibers: an Alternative Therapy Scheme for Local Treatment of Vulvovaginal Candidiasis. ( 29940181 )
2018
16
Antimicrobial photodynamic therapy as a new approach for the treatment of vulvovaginal candidiasis: preliminary results. ( 29931589 )
2018
17
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. ( 29932786 )
2018
18
RISK FACTORS OF VULVOVAGINAL CANDIDIASIS IN DERMATO-VENEREOLOGY OUTPATIENTS CLINIC OF SOETOMO GENERAL HOSPITAL, SURABAYA, INDONESIA. ( 29619437 )
2018
19
Longitudinal trajectory of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis during pregnancy as well as the impact on pregnancy outcomes: a preliminary study. ( 29685081 )
2018
20
A Therapeutic Vaccine for Recurrent Vulvovaginal Candidiasis. ( 29697770 )
2018
21
A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. ( 29697768 )
2018
22
Computer-aided diagnosis software for vulvovaginal candidiasis detection from Pap smear images. ( 28987021 )
2018
23
Development, characterization, and in vitro-in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis. ( 29361177 )
2018
24
Mannose-Binding Lectin Gene Polymorphism and Its Association with Susceptibility to Recurrent Vulvovaginal Candidiasis. ( 29850562 )
2018
25
Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. ( 30184181 )
2018
26
Inhibition of CXCR4 by MicroRNA-1192 Reduces the Activation of Th17 Cells and Expression of Inflammation Factors in a Mouse Model of Vulvovaginal Candidiasis. ( 30355939 )
2018
27
Nystatin enhances the immune response against Candida albicans and protects the ultrastructure of the vaginal epithelium in a rat model of vulvovaginal candidiasis. ( 30359236 )
2018
28
Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis. ( 30425538 )
2018
29
Biofilms and vulvovaginal candidiasis. ( 30447520 )
2018
30
In vivo applicability of Neosartorya fischeri antifungal protein 2 (NFAP2) in treatment of vulvovaginal candidiasis. ( 30478163 )
2018
31
Miconazole loaded chitosan-based nanoparticles for local treatment of vulvovaginal candidiasis fungal infections. ( 30481701 )
2018
32
Concerns regarding bias in estimates of recurrent vulvovaginal candidiasis. ( 30507400 )
2018
33
IL-9 Integrates the Host-Candida Cross-Talk in Vulvovaginal Candidiasis to Balance Inflammation and Tolerance. ( 30515173 )
2018
34
Influence of Nursing Intervention on Recurrent Vulvovaginal Candidiasis Patients Treated with ATP-infrared Bio-effect Technique. ( 30524981 )
2018
35
Types of yeasts that cause vulvovaginal candidiasis in chronic users of corticosteroids. ( 30544194 )
2018
36
Formulation, stability study and preclinical evaluation of a vaginal cream containing curcumin in a rat model of vulvovaginal candidiasis. ( 29517833 )
2018
37
Contribution of TLR2 pathway in the pathogenesis of vulvovaginal candidiasis. ( 30052917 )
2018
38
Epitope unmasking in vulvovaginal candidiasis is associated with hyphal growth and neutrophilic infiltration. ( 30063729 )
2018
39
Vulvovaginal candidiasis in reproductive age women in Enugu Nigeria, clinical versus laboratory-assisted diagnosis. ( 30074004 )
2018
40
Global burden of recurrent vulvovaginal candidiasis: a systematic review. ( 30078662 )
2018
41
The changes of antifungal susceptibilities caused by the phenotypic switching of Candida species in 229 patients with vulvovaginal candidiasis. ( 30101450 )
2018
42
Vaginal lipidomics of women with vulvovaginal candidiasis and cytolytic vaginosis: A non-targeted LC-MS pilot study. ( 30133508 )
2018
43
The Relationship Between Vulvovaginal Candidiasis and Provoked Vulvodynia: A Systematic Review. ( 30145093 )
2018
44
Curcumin-Loaded Liquid Crystalline Systems for Controlled Drug Release and Improved Treatment of Vulvovaginal Candidiasis. ( 30184431 )
2018
45
Prevalence of vulvovaginal candidiasis in gynecological practices in Germany: A retrospective study of 954,186 patients. ( 30186987 )
2018
46
Candida africana in recurrent vulvovaginal candidiasis (RVVC) patients: frequency and phenotypic and genotypic characteristics. ( 30248002 )
2018
47
Alternative and complementary therapies for vulvovaginal candidiasis. ( 30269301 )
2018
48
Natural products for vulvovaginal candidiasis treatment: evidence from clinical trials. ( 30277156 )
2018
49
Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen? ( 28868834 )
2017
50
Recurrent vulvovaginal candidiasis: A review of guideline recommendations. ( 28299777 )
2017
Sources

Variations for Vulvovaginal Candidiasis

About this section
Sources

Expression for Vulvovaginal Candidiasis

About this section
Search GEO for disease gene expression data for Vulvovaginal Candidiasis.
Sources

Pathways for Vulvovaginal Candidiasis

About this section

Pathways related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 12.92 CD101 CD79A CLEC7A DEFB1 DEFB4A IL2
2
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 12.7 IL2 MBL2 NLRP3 TLR2
3
Influenza A 37
Show member pathways
 12.36 IL2 IL4 NLRP3 TLR2
4
Defensins 66
Show member pathways
 12.07 DEFB1 DEFB4A TLR2
5
IL-17 Family Signaling Pathways 65
Show member pathways
 12.02 DEFB4A IL4 TLR2
6
NF-kappaB Signaling 4
11.97 CD79A IL2 IL4 TLR2
7
C-type lectin receptor signaling pathway 37
Show member pathways
 11.85 CLEC7A IL2 NLRP3
8
Bacterial infections in CF airways 22
Show member pathways
 11.8 DEFB4A IL4 TLR2
9
Phagosome 37
11.68 CLEC7A MBL2 TLR2
10
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.5 CD79A IL2 IL4
11
Th2 Differentiation Pathway 65
11.22 IL2 IL4
12
Inflammatory Response Pathway 1
11.04 IL2 IL4
13
Innate Lymphoid Cell Differentiation Pathways 65
11.03 CD101 IL2 IL4
14
Cytokines and Inflammatory Response 1
10.96 IL2 IL4
15
OX40 Pathway 64
10.89 IL2 IL4
16
IL1 and megakaryocytes in obesity 1
10.85 NLRP3 TLR2
Sources

GO Terms for Vulvovaginal Candidiasis

About this section

Cellular components related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.1 DEFB1 DEFB4A IL2 IL4 MBL2 NLRP3

Biological processes related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.72 CLEC7A DEFB1 MBL2 NLRP3 TLR2
2 defense response to bacterium GO:0042742 9.69 DEFB1 DEFB4A MBL2
3 immune response GO:0006955 9.65 DEFB1 DEFB4A IL2 IL4 TLR2
4 defense response GO:0006952 9.61 DEFB1 DEFB4A NLRP3
5 T cell activation GO:0042110 9.52 CLEC7A IL4
6 positive regulation of B cell proliferation GO:0030890 9.49 IL2 IL4
7 B cell activation GO:0042113 9.48 CD79A IL4
8 positive regulation of T cell differentiation GO:0045582 9.46 IL2 IL4
9 immune system process GO:0002376 9.43 CD79A CLEC7A IL2 MBL2 NLRP3 TLR2
10 positive regulation of isotype switching to IgG isotypes GO:0048304 9.4 IL2 IL4
11 positive regulation of interleukin-13 production GO:0032736 9.37 IL4 NLRP3
12 cytokine secretion involved in immune response GO:0002374 9.16 NLRP3 TLR2
13 defense response to Gram-positive bacterium GO:0050830 9.02 DEFB1 DEFB4A MBL2 NLRP3 TLR2

Molecular functions related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.43 CLEC7A IL2 MBL2
2 peptidoglycan binding GO:0042834 9.16 NLRP3 TLR2
3 signaling pattern recognition receptor activity GO:0008329 8.96 CLEC7A TLR2
4 CCR6 chemokine receptor binding GO:0031731 8.62 DEFB1 DEFB4A
Sources

Sources for Vulvovaginal Candidiasis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....